<< Back To Home Live Attenuated Chimeric Vaccine, rWN/DEN4Δ30 is Well-Tolerated and Immunogenic in Flavivirus-Naïve Older Adult Volunteers [West Nile Virus]
Printable Copy |
|
Live Attenuated Chimeric Vaccine, rWN/DEN4Δ30 is Well-Tolerated and Immunogenic in Flavivirus-Naïve Older Adult Volunteers
- Kristen K. Pierce1,*,
- Stephen S. Whitehead3,
- Beth D. Kirkpatrick1,
- Palmtama L. Grier2,
- Adrienne Jarvis1,
- Heather Kenney3,
- Marya P. Carmolli1,
- Cynthia Reynolds1,
- Cecilia M. Tibery2,
- Janece Lovchik2,
- Anna Janiak2,
- Catherine J. Luke3,
- Anna P. Durbin2 and
- Alexander G. Pletnev3
- Author Affiliations
- 1Vaccine Testing Center, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA
- 2Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 3Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
- ↵*Correspondence: K. K. Pierce, Vaccine Testing Center, Department of Medicine, University of Vermont College of Medicine, 89 Beaumont Ave, Given Building C205, Burlington, VT 05405, Phone: 802-847-3819, Fax 802-847-5322 (Kristen.pierce@uvmhealth.org).
The Journal of Infectious Diseases
Abstract below; full text is available to journal subscribers.
West Nile virus (WNV), a major cause of mosquito-borne illness in the U.S. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults over 60 are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults ages 18-50. This study evaluated the rWN/DEN4Δ30 vaccine in flavivirus-naive adults age 50-65, and found it to be safe and immunogenic. Outbreaks of WNV tend to be unpredictable, a safe and effective vaccine will be an important public health tool.
- © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.